Evenity (romosozumab; Amgen/UCB/Astellas) is a novel humanized monoclonal antibody therapy targeting the osteocyte-produced protein sclerostin, which inhibits bone formation in osteoblastic cells. As such, Evenity has an anabolic effect, and is being developed as a treatment for postmenopausal women with osteoporosis. Sclerostin is a key part of the negative feedback loop that acts to control the activity of osteoblastic cells. Knockout mice for SOST, the gene encoding sclerostin, show an increase in bone formation, resulting in greater bone mass and strength.
It is hypothesized that by inhibiting the activity of sclerostin as opposed to the activity of osteoclasts or osteoblasts directly, Evenity acts to uncouple the bone formation and bone resorption processes. This prevents the rebound increase in osteoclastic bone resorption that can be seen when parathyroid or parathyroid hormone-related peptides are used. This has been illustrated in both animal and human studies.
LIST OF FIGURES 10 Figure 1: Evenity for osteoporosis – SWOT analysis
11 Figure 2: Datamonitor Healthcare’s drug assessment summary of Evenity for osteoporosis
12 Figure 3: Datamonitor Healthcare’s drug assessment summary of Evenity for osteoporosis
LIST OF TABLES 6 Table 1: Evenity drug profile
8 Table 2: Evenity pivotal trial data in osteoporosis
9 Table 3: Evenity other late-phase trials in osteoporosis
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.